Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05418010 |
|---|---|
| Brief Title: | Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) (AttackMS) |
| First Submitted : | February 17, 2022 |
| First Submitted that Met QC Criteria : | June 10, 2022 |
| First Posted : | June 14, 2022 |
| Last Update Submitted that Met QC Criteria : | May 19, 2023 |
| Last Update Posted : | May 22, 2023 |